Skip to main content

Table 3 Univariate and Multivariate Cox regression analysis for all cases of Cohort 1 (n = 758)

From: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

 

Univariate

Multivariate

OS

PFS

OS

PFS

HR

95 % C.I.

p-value

HR

95 % C.I.

p-value

HR

95 % C.I.

p-value

HR

95 % C.I.

p-value

Histology

Astro grade II

0.91

0.518–1.594

0.74

1.23

0.788–1.906

0.37

0.58

0.323–1.027

0.06

0.92

0.585–1.461

0.74

Astro grade III

2.14

1.410–3.245

0.0003

1.85

1.291–2.638

0.0008

1.02

0.658–1.566

0.95

0.99

0.682–1.447

0.97

GBM

4.02

2.860–5.635

<0.0001

3.73

2.801–4.974

<0.0001

1.24

0.842–1.813

0.28

1.43

1.024–1.989

0.04

Oligo grade II

0.25

0.127–0.504

<0.0001

0.48

0.313–0.749

0.001

0.42

0.207–0.846

0.02

0.6

0.381–0.928

0.02

Oligo grade III

Ref

Ref

Ref

Ref

Molecular group*

Group A

0.04

0.023–0.073

<0.0001

0.1

0.070–0.142

<0.0001

0.09

0.048–0.180

<0.0001

0.19

0.124–0.296

<0.0001

Group B

0.12

0.079–0.184

<0.0001

0.18

0.126–0.242

<0.0001

0.29

0.172–0.480

<0.0001

0.33

0.218–0.492

<0.0001

Group C

0.58

0.454–0.735

<0.0001

0.62

0.499–0.773

<0.0001

0.71

0.545–0.919

0.01

0.7

0.553–0.888

0.003

Group D

Ref

Ref

Ref

Ref

Location

Cerebrum

0.79

0.482–1.305

0.36

0.65

0.430–0.985

0.04

excluded by the factor selection with step-wise method

0.67

0.427–1.045

0.08

Cerebrum with frontal Involvement

0.40

0.242–0.670

0.0005

0.31

0.203–0.475

<0.0001

0.5

0.316–0.779

0.002

Other

Ref

Ref

Ref

Age

 

1.048a

1.040–1.057

<0.0001

1.033a

1.027–1.040

<0.0001

1.02a

1.011–1.029

<0.0001

1.01a

1.003–1.018

0.007

Sex

M

Ref

Ref

Ref

Ref

F

0.91

0.724–1.134

0.39

0.95

0.781–1.150

0.58

0.72

0.572–0.905

0.005

0.81

0.663–0.982

0.03

KPS

0.971b

0.965–0.976

<0.0001

0.98b

0.974–0.985

<0.0001

0.99b

0.983–0.997

0.008

excluded by factor selection with step-wise method

Surgery

Biopsy

1.85

1.416–2.427

<0.0001

1.41

1.092–1.817

0.008

2.05

1.522–2.755

<0.0001

1.6

1.204–2.121

0.001

 

Removal

Ref

Ref

Ref

Ref

Adjuvant Therapy

CRT

2.02

1.132–3.601

0.02

1.78

1.110–2.868

0.02

excluded by factor selection with step-wise method

excluded by factor selection with step-wise method

Chemo

0.84

0.392–1.792

0.65

0.87

0.472–1.587

0.64

RT

Ref

Ref

None

0.45

0.197–1.010

0.05

0.74

0.411–1.333

0.32

  1. Astro grade II diffuse astrocytoma, Astro grade III anaplastic astrocytoma, Chemo Chemotherapy, C.I. Coefficient interval, CRT chemoradiotherapy, F Female, GBM glioblastoma, HR hazard ratio, KPS Karnofsky Performance status, M Male, mut mutatant, Oligo grade II oligodendroglioma and oligoastrocytoma, Oligo grade III anaplastic oligodendroglioma and anaplastic oligoastrocytoma, OS overall survival, PFS progression free survival, Ref Reference, RT radiation therapy, wt wild type
  2. * Group A IDH mutated-TERT mutated, Group B IDH mutated-TERT wid-type, Group C IDH wild-type-TERT wild-type, Group D IDH mutated-TERT mutated
  3. a HR is for each one year increase, b HR is for each 1 % increase
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us